Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

Sep 20, 2017
4:30 PM ET




Stock Quote

NASDAQ: ARGS
0.17
- 0.00 (-2.53%)

Day High:
0.17

Day Low:
0.16

Volume:
2,767,077

3:59 PM ET on Oct 17, 2017
Delayed at least 20 minutes.

Tweets